Boston, MA – [Insert Date] – Alkermes plc today announced encouraging top-line results from its pivotal Phase III REVITALYZ study, evaluating the investigational use of extended-release Lumryz (sodium oxybate) oral suspension in adults suffering from idiopathic hypersomnia (IH). The study met its primary endpoint, demonstrating a statistically significant benefit of Lumryz over placebo in improving excessive daytime sleepiness (EDS) and related symptoms in individuals with this rare neurological sleep disorder. These positive findings pave the way for a potential new treatment option for a patient population with historically limited therapeutic choices.
Idiopathic hypersomnia is a chronic and debilitating neurological condition characterized by profound and persistent daytime sleepiness, even after adequate durations of nighttime sleep. Individuals with IH often struggle with an overwhelming urge to sleep, leading to significant impairments in daily functioning, cognitive abilities, and overall quality of life. The exact cause of IH remains unknown, adding to the diagnostic and therapeutic challenges faced by patients and clinicians alike.
The randomized withdrawal, placebo-controlled, multi-center, double-blind REVITALYZ study enrolled 104 participants. The trial design incorporated robust methodology to assess the efficacy and safety of Lumryz. Following an open-label dose titration and stable dose period, where all participants received Lumryz, they were then randomized to either continue Lumryz or switch to a placebo. This design allowed for a direct comparison of Lumryz’s maintenance of effect against placebo withdrawal.
Chronology of the REVITALYZ Study and Key Milestones
The REVITALYZ study progressed through distinct phases, meticulously designed to capture comprehensive data on Lumryz’s impact on idiopathic hypersomnia.
1. Open-Label Dose Titration and Stable Dose Period:
During this initial phase, all 104 enrolled participants received Lumryz. This period served a dual purpose: to establish an optimal and safe dosage for each individual and to gather baseline data on the drug’s initial effects. Crucially, during this open-label phase, participants consistently demonstrated improvements in their Epworth Sleepiness Scale (ESS) scores. The ESS is a widely recognized tool for measuring daytime sleepiness, with higher scores indicating greater severity. The observed improvement in ESS scores during this period provided an early indication of Lumryz’s potential efficacy.
2. Randomized Withdrawal Period:
Following the stabilization of Lumryz dosage, participants entered the double-blind, placebo-controlled phase. At this juncture, participants were randomly assigned to one of two treatment arms:
- Lumryz Group: Continued treatment with Lumryz.
- Placebo Group: Switched to a placebo, while remaining blinded to their treatment assignment.
This randomized withdrawal design is a gold standard in clinical trials for chronic conditions, allowing researchers to isolate the specific effect of the active treatment by observing the consequences of its discontinuation. The double-blind nature of this phase ensured that neither the participants nor the investigators were aware of who was receiving Lumryz and who was receiving placebo, thereby minimizing potential bias.
3. Primary Endpoint Assessment:
The primary endpoint of the REVITALYZ study was assessed at the conclusion of the randomized withdrawal period. This endpoint focused on the change in ESS scores from the end of the stable dose period to the end of the double-blind randomized withdrawal period. The statistical analysis of this data was critical in determining whether Lumryz demonstrated a statistically significant benefit in maintaining reduced daytime sleepiness compared to placebo.
4. Secondary Endpoint Evaluation:
In addition to the primary endpoint, the study meticulously evaluated several key secondary endpoints. These included the Patient Global Impression of Change (PGI-C) and the Idiopathic Hypersomnia Severity Scale (IHSS). The PGI-C is a subjective measure of how much a patient’s condition has improved or worsened from their perspective, offering valuable patient-reported outcomes. The IHSS is another clinical scale designed to quantify the severity of IH symptoms. These secondary endpoints provided a more comprehensive understanding of Lumryz’s impact on various facets of the disease.
5. Safety Monitoring:
Throughout all phases of the study, rigorous safety monitoring was conducted. Adverse events were systematically recorded and analyzed to assess the safety profile of Lumryz in the IH population.
Supporting Data: Quantifying Lumryz’s Impact
The top-line data from the REVITALYZ study revealed a clear and statistically significant benefit for Lumryz in treating idiopathic hypersomnia. The primary endpoint was met, with participants who continued Lumryz treatment exhibiting a significantly lower worsening of ESS scores compared to those who were switched to placebo. This indicates that Lumryz effectively maintained reduced levels of daytime sleepiness.
Furthermore, the secondary endpoints corroborated the positive findings of the primary endpoint. Participants in the Lumryz arm demonstrated significantly less worsening on the Patient Global Impression of Change (PGI-C) and the Idiopathic Hypersomnia Severity Scale (IHSS) compared to the placebo group. This suggests that Lumryz not only improved sleepiness but also positively impacted patients’ overall perception of their condition and the severity of their IH symptoms.
The statistical significance observed across these endpoints underscores the clinical meaningfulness of Lumryz’s effect. For individuals living with the debilitating burden of idiopathic hypersomnia, even modest improvements in sleepiness and overall well-being can translate into substantial gains in daily functioning, productivity, and quality of life.
Regarding safety, the REVITALYZ study’s findings were consistent with Alkermes’ prior observations of Lumryz. The investigational drug maintained a favorable safety profile, and no new safety signals were identified during the study. The most frequently reported adverse events, occurring in 10% or more of participants, included anxiety, dizziness, headache, nausea, and vomiting. This established safety profile is crucial for a chronic condition like IH, where long-term treatment may be necessary.
Official Responses: A Beacon of Hope for Patients
Alkermes has expressed significant enthusiasm regarding the positive results of the REVITALYZ study. Craig Hopkinson, Alkermes’ Chief Medical Officer and Executive Vice President of Research and Development, highlighted the study’s compelling outcomes.
"We are very encouraged by the clear and compelling outcome of the REVITALYZ study and look forward to advancing Lumryz as a potential treatment for adults with idiopathic hypersomnia," stated Dr. Hopkinson. He further emphasized Alkermes’ commitment to addressing unmet needs in sleep medicine. "Historically, people living with sleep disorders have had limited treatment options from which to choose, and Alkermes is motivated to contribute to the overall clinical landscape of sleep medicine through research such as this."
This sentiment underscores the critical need for new therapeutic avenues for individuals with IH. The current treatment landscape for this condition is sparse, leaving many patients struggling to manage their symptoms effectively. Alkermes’ dedication to developing innovative treatments for sleep disorders, including IH, offers a renewed sense of hope for this underserved patient population.
Alkermes has announced its intention to present detailed results from the REVITALYZ study at an upcoming medical meeting. This will provide the broader scientific and medical community with an opportunity to scrutinize the data and further understand Lumryz’s potential. Additionally, the company plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) by the end of this year. This submission will seek to expand the approved indication of Lumryz to include the treatment of idiopathic hypersomnia in adults.
It is important to note that while Lumryz is currently approved by the FDA for the treatment of excessive daytime sleepiness or cataplexy in patients seven years of age and older with narcolepsy, its use for IH is still investigational. Alkermes is subject to a regulatory agreement that restricts the marketing of Lumryz for IH prior to March 1, 2028. This timeline reflects the regulatory process and the need for thorough review of the submitted data.
In parallel with the advancement of Lumryz, Alkermes is also actively exploring other therapeutic targets for IH. In April 2025, the company initiated a randomized Phase II trial to assess the efficacy and safety of ALKS 2680, another investigational compound, in adults with IH. This dual-pronged approach demonstrates Alkermes’ commitment to a comprehensive strategy in addressing the complex challenges of idiopathic hypersomnia.
Implications and Future Outlook
The positive Phase III results from the REVITALYZ study represent a significant step forward in the treatment of idiopathic hypersomnia. If approved, Lumryz could offer a much-needed therapeutic option for adults struggling with the pervasive and life-altering symptoms of IH. The drug’s ability to significantly reduce daytime sleepiness and improve overall well-being, as demonstrated by the study’s primary and secondary endpoints, holds the promise of restoring functionality and improving the quality of life for countless individuals.
The implications extend beyond individual patient benefits. The success of Lumryz in IH could also stimulate further research and development in the broader field of sleep medicine. By validating novel therapeutic approaches and demonstrating the potential for significant clinical impact, Alkermes’ work may encourage other pharmaceutical companies to invest in the development of treatments for rare and complex sleep disorders.
The upcoming FDA submission and presentation of detailed data will be critical milestones. The scientific and regulatory review processes will rigorously assess the evidence, ensuring that any potential approval is based on a robust understanding of Lumryz’s efficacy and safety. The regulatory agreement regarding marketing exclusivity for IH also highlights the structured approach to introducing new treatments for this condition.
Looking ahead, the landscape of idiopathic hypersomnia treatment may soon be transformed by Lumryz. The ongoing research, including the Phase II trial of ALKS 2680, further solidifies Alkermes’ position as a key player in the development of innovative sleep disorder therapies. For individuals living with IH, the REVITALYZ study results offer a tangible reason for optimism, signaling a potential future where this debilitating condition can be more effectively managed, leading to improved health outcomes and a better quality of life.
About the Author
